The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

VJVirtual | Enasidenib for IDH2-mutated MDS

Name: Enasidenib for IDH2-mutated MDS
Uploaded: 2020-03-17T00:00:00Z
Duration: 1 min 13 s
Description: Valeria Santini, MD, University of Florence, Florence, Italy, gives us a round-up of some of the exciting trials currently taking place in the myelodysplastic syndromes (MDS) space. Specifically, Dr Santini outlined the use of enasidenib for IDH2-mutated MDS. This interview was filmed via an online conference call with VJHemOnc.

Valeria Santini • 17 Mar 2020

Myelodysplastic Syndromes Enasidenib

Valeria Santini, MD, University of Florence, Florence, Italy, gives us a round-up of some of the exciting trials currently taking place in the myelodysplastic syndromes (MDS) space. Specifically, Dr Santini outlined the use of enasidenib for IDH2-mutated MDS. This interview was filmed via an online conference call with VJHemOnc.